AstraZeneca Pharma India Limited

As of June 30, 2026, AstraZeneca Pharma India Limited carries a market capitalization of 205.40B, placing it among publicly traded companies globally. Its enterprise value stands at 205.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, AstraZeneca Pharma India Limited has 25.00M shares outstanding.

As of June 30, 2026, AstraZeneca Pharma India Limited trades at a trailing price-to-earnings ratio of 121.09.

As of June 30, 2026, AstraZeneca Pharma India Limited trades at an EV/EBITDA multiple of 91.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 98.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 205.40B versus a market cap of 205.40B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 31.14M in revenue per employee across its workforce of 781.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, AstraZeneca Pharma India Limited recorded 586.30M in income tax expense. That works out to an effective tax rate of 25.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.28B, leaving 1.70B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, AstraZeneca Pharma India Limited's stock has declined approximately 34.43% over the past 52 weeks. The 50-day moving average sits at 6,713.29, while the 200-day moving average is 7,993.27.

Over the twelve months ended June 30, 2026, AstraZeneca Pharma India Limited generated 24.32B in revenue and converted that into 1.70B in net income, yielding earnings per share of 67.85. EBITDA reached 2.25B, while operating income came in at 2.13B.

Over the twelve months ended June 30, 2026, AstraZeneca Pharma India Limited posted a gross margin of 36.99, reflecting its pricing power and cost economics. The operating margin of 8.74 and net profit margin of 6.97 provide insight into operational efficiency.

AstraZeneca Pharma India Limited's most recent stock split took place on June 15, 2006 with a 1:5 split ratio.